PTCG
TEVA icon

Pring Turner Capital Group’s Teva Pharmaceuticals TEVA Stock Holding History

Pring Turner Capital Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-334
Closed -$13K – 161
2013
Q4 		$13K Buy
+334
New +$13.2K 0.01% 165

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

Pring Turner Capital Group's TEVA Position: Q1 2014 in Review

Pring Turner Capital Group sold out of Teva Pharmaceuticals (TEVA) in Q1 2014, closing a stake of 334 shares — an estimated $13K sold.

Pring Turner Capital Group first reported a position in TEVA in Q4 2013 and held it in 1 quarter. The position peaked at $13K in Q4 2013. 770 funds tracked by Wall St. Rank hold TEVA as of Q1 2014.

  • Pring Turner Capital Group reported no remaining Teva Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Pring Turner Capital Group sold 334 Teva Pharmaceuticals shares in Q1 2014, an estimated $13K.
  • Pring Turner Capital Group first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 1 quarter.
  • Pring Turner Capital Group's Teva Pharmaceuticals position peaked at $13K in Q4 2013.
  • 770 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2014.

Based on Pring Turner Capital Group's 13F filing for Q1 2014, filed 14 May 2014.